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Self-management education for adults with
poorly controlled epilepsy (SMILE (UK)):
statistical, economic and qualitative analysis
plan for a randomised controlled trial
Nicholas Magill1*, Leone Ridsdale2, Laura H. Goldstein3, Paul McCrone4, Myfanwy Morgan5, Adam J. Noble6,
Gus Baker7, Mark Richardson2, Stephanie Taylor8 and Sabine Landau1
Abstract
Background: There is a need to test the effectiveness of new educational interventions for people with poorly
controlled epilepsy. The SMILE (self-management education for adults with poorly controlled epilepsy) trial
evaluates a complex service intervention that involves a 2-day self-management course with the aim of improving
quality of life and clinical outcomes. This article describes the statistical, economic, and qualitative analysis plan for
the trial.
Methods and design: SMILE is a pragmatic, parallel design, two-arm, multi-centre randomised controlled superiority
trial of a group-based interactive course compared with treatment as usual for people who have experienced two or
more seizures in the past 12 months.
Results: A summary of the objectives and design of the trial are reported as well as the manner in which the data will
be summarised and inferentially analysed. This includes the type of modelling that will be employed for each of the
primary and secondary outcomes and the methods by which the assumptions of these models will be checked.
Strategies are described for handling clustering of outcome data, missing observations, and treatment non-compliance.
Conclusion: This update to the previously published trial protocol provides a description of the trial analysis which is
transparent and specified before any outcome data are available. It also provides guidance to those planning the
analysis of similar trials.
Trial registration: Current Controlled Trials ISRCTN57937389; date assigned: 27 March 2013.
Keywords: Statistical analysis plan, SMILE trial, epilepsy, self-management education, randomised controlled trial
Update
Background
Epilepsy
Epilepsy is a long-term neurological condition, which af-
fects approximately 1 % of the UK population [1]. After
diagnosis, roughly 40 % of patients continue to experi-
ence at least two seizures per year [2] and the conse-
quences for this group include elevated risks of injury,
depression, and premature death [1]. From the perspec-
tive of health service provision, poorly controlled epi-
lepsy is expensive (€2,000–€11,500 per case in 2004) [3].
The overwhelming majority of admissions for epilepsy
are on an emergency basis [4], making it the sixth most
common cause of emergency admission for chronic con-
ditions in the UK [5] and adding considerably to health-
care cost.
Providing patients with the ability to manage long-
term conditions and reducing emergency admissions are
key aims of the National Health Service (NHS). For
people with poorly controlled epilepsy, this means in-
creasing patients’ confidence in their ability to recognise
* Correspondence: nicholas.magill@kcl.ac.uk
1Department of Biostatistics, Institute of Psychiatry, Psychology and
Neuroscience, King’s College London, PO 20, Denmark Hill Campus, 16 De
Crespigny Park, London SE5 8AF, UK
Full list of author information is available at the end of the article
TRIALS
© 2015 Magill et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Magill et al. Trials  (2015) 16:269 
DOI 10.1186/s13063-015-0788-9
triggers for seizures [6] and improving their adherence
to antiepileptic drugs (AEDs) [7, 8]. Routine NHS pol-
icy for another chronic illness, diabetes, is the offer of
group education (e.g., diabetes education and self-
management for ongoing and newly diagnosed, or
DESMOND [9]), and there is now demand for similar
courses for those with epilepsy. This is supported by
the finding that a third of those with poorly controlled
epilepsy have been told little about the disease and the
side effects of AEDs [10].
Of a number of epilepsy interventions reviewed by
the Cochrane collaboration [11, 12], only one has been
thoroughly assessed and shown potential benefit in the
UK. This group intervention was developed in
Germany, where it was called Modular Service Package
in Epilepsy (MOSES) [13]. A trial of this reported im-
proved knowledge about the condition, enhanced con-
trol of seizures, and better acceptance of AEDs. The
intervention has been adapted for use in the UK and is
referred to here as the SMILE (self-management educa-
tion for adults with poorly controlled epilepsy) trial.
SMILE trial
The SMILE trial is a parallel design, two-arm, multi-
centre randomised controlled superiority trial of a 2-day
self-management course for adults with poorly con-
trolled epilepsy. Participants are randomly allocated to
receive either SMILE and treatment as usual (TAU) or
TAU alone, and randomisation is stratified by treatment
centre. The aim is to test whether the intervention af-
fects quality of life, clinical outcomes, and cost-
effectiveness of health service use at 6 and 12 months
after randomisation. Blinding is planned for outcome as-
sessors and the trial statistician. See protocol article for
further details [14].
This article describes the statistical analysis plan for
the main analyses of the trial. The plan was finalised and
approved by the Trial Steering Committee on 3 March
2014, before any outcome data were available.
Research questions
Primary objective
The primary objective is to examine the treatment differ-
ence in Quality of Life in Epilepsy-31 (QOLIE-31) [15]
scores between participants allocated to self-management
education (SMILE) versus those allocated to TAU at 12
months after randomisation.
Secondary objectives
The secondary objectives are the following:
1. To investigate the treatment difference in QOLIE-31
between participants allocated to SMILE and those
allocated to TAU at 6 months after randomisation.
2. To investigate the treatment effect on seizure
frequency as recorded using the scale of Baker et al.
[16] between participants allocated to SMILE and
those allocated to TAU at 6 and 12 months after
randomisation.
3. To investigate the treatment effect on seizure
frequency as recorded using the scale of Thapar
et al. [17] between participants allocated to SMILE
and those allocated to TAU at 6 and 12 months after
randomisation.
4. To investigate the treatment effect on time elapsed
since last seizure of allocation to SMILE compared
with those offered TAU at 6 and 12 months after
randomisation.
5. To investigate the treatment difference in self-
perceived impact of epilepsy (as measured by the
Impact of Epilepsy scale [18]) between those allocated
to SMILE and those offered TAU at 6 and 12 months
after randomisation.
6. To investigate the treatment difference in
medication management as measured by the
Epilepsy Self-Management Questionnaire [7]
between participants allocated to SMILE and those
allocated to TAU at 12 months after
randomisation.
7. To investigate the treatment difference in
medication adverse events (AEs) as measured by two
questions from QOLIE-31 [15] between participants
allocated to SMILE and those allocated to TAU at 6
and 12 months after randomisation.
8. To investigate the treatment effect on psychological
distress as measured by the Hospital Anxiety and
Depression Scale (HADS) [19] between participants
allocated to SMILE and those allotted to TAU at 12
months after randomisation.
9. To investigate the treatment difference in perceived
stigma as measured by Jacoby’s Stigma of Epilepsy
scale [20] between participants allocated to SMILE
and those allotted to TAU at 12 months after
randomisation.
10.To investigate the treatment effect on self-efficacy in
management of epilepsy (using the mastery/control
of epilepsy scale [21]) between participants allocated
to SMILE and those allocated to TAU at 12 months
after randomisation.
11.To investigate the treatment difference in cost-
effectiveness of health service use between participants
randomly assigned to SMILE and those randomly
assigned to TAU at 12 months after randomisation.
12.To conduct an in-depth qualitative interview study to
investigate SMILE users’ views on their participation
in, and the perceived benefits of, the intervention.
See protocol for further details of measures [14].
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Trial design
Recruitment procedure and randomisation
Research workers visit participants at their home or a
place of their choice and explain the trial in detail.
Those individuals who meet the eligibility criteria are
asked to provide informed written consent and base-
line assessments. Consenting individuals who provide
baseline data are randomly assigned to one of the
treatment arms in a 1:1 ratio. See Fig. 1 for an illustra-
tion of the process by which patients are screened,
recruited, randomly assigned, and followed up. Ran-
domisation is at the patient level and is performed by
using an online randomisation system set up by the
King’s Clinical Trials Unit (KCTU) at the Institute of
Psychiatry, Psychology and Neuroscience in London.
Randomisation is stratified by treatment centre. A set
of patients is randomly assigned with fixed block sizes
of two to ensure that equal numbers of patients are al-
located to the two arms within each treatment centre.
The procedure is as follows: on receipt of the baseline
questionnaire and after between 14 and 24 partici-
pants have been recruited to a site, the trial coordin-
ator electronically submits details of the set of
participants to the KCTU. The system immediately
notifies the trial coordinator of successful randomisa-
tion and the trial arm to which the participant has
been allocated. A record of the allocation outcome is
kept in the KCTU randomisation database and later
linked to the main dataset.
Ethical approval was given by the National Research
Ethics Service London – Fulham (reference 12/LO/
1962).
Fig. 1 CONSORT (Consolidated Standards of Reporting Trials) diagram. SMILE self-management education for adults with poorly
controlled epilepsy
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Sample size
The primary intention-to-treat (ITT) analyses will com-
pare two equal-sized treatment arms, treatment or con-
trol, on the quality-of-life scale (QOLIE-31) at 12
months. Two drug trials that used this scale as an out-
come showed standardised effect sizes of d = 0.33 [22]
and 0.59 [23]. An overall sample size of 320 participants
(randomly assigned 1:1) would provide 91.3 % power to
detect an effect size of d = 0.40 on the QOLIE-31 using
an analysis of covariance with two-sided 5 % significance
tests. A value of d = 0.40 corresponds to a change of
around 6–7 points on the overall quality-of-life score.
Since the active treatment is a group treatment deliv-
ered by different educational facilitators within sites, we
must allow for standard error inflation due to training
group effects. Assuming an average group size of 10
people with epilepsy and an intra-group correlation be-
tween QOLIE-31 scores of intra-class correlation coeffi-
cient (ICC) equal to 0.025 (a correlation of 0.05 would
be expected for intermediate outcomes but would be
lower for distal outcomes such as quality of life [24]), we
estimated that 160 patients in the control arm and 16
groups of 10 patients in the SMILE arm would provide
91.3 % power to detect an effect of d = 0.40.
The estimated attrition rate was based on data from a
study of rehabilitation for people with severe epilepsy
which had a 25 % loss at 1 year (NIHR SDO 08/1815/
234). Therefore, to ensure adequate and equal-sized
groups, a sample of 428 patients is required (n = 320/
0.75; 214 patients per arm).
Timing and visit windows of follow-up
Participants will complete a limited selection of follow-
up measures at 6 months after randomisation by using a
questionnaire sent to them in the post. This comprises
quality of life, seizure frequency, time elapsed since last
seizure, and impact of epilepsy. The full range of follow-
up measures will be completed at 12 months after
randomisation by face-to-face interview with a research
assistant. The aim is for follow-up assessments to be col-
lected within 3 weeks of the intended date.
Minimising attrition
It is expected that some participants will be lost to
follow-up and this has been accounted for in the sample
size calculation. However, every effort will be made to
minimise such attrition, by following the recommenda-
tions of recent research [25]. A sequence of telephone
reminders will be used to maximise the collection of
follow-up data, especially at the 6-month assessment.
This assessment has been specifically condensed in order
to reduce patient burden. An additional measure to in-
crease adherence is the distribution of £20 vouchers fol-
lowing the 12-month assessment.
Blinding
Outcome assessors and the trial statistician will be blind
to participants’ allocated treatment arm. At the start of
each follow-up assessment, interview participants are re-
quested not to reveal to the researcher which group they
were allocated to. If a researcher is unblinded at the 6-
month outcome visit, a different researcher will conduct
the next follow-up assessment. Additionally, the trial da-
tabases have been designed specifically to enable data
entry without unblinding researchers. This has been
achieved by creating separate databases for recording
outcome data, course attendance, and educational facili-
tator information. We are assessing how well researchers
were kept blind by asking the assessor to make a guess
as to which treatment each participant was allocated to
at the end of follow-up.
Reporting
The trial results will be reported in a manner that is
consistent with the recommendations of the updated
CONSORT (Consolidated Standards of Reporting Trials)
guidelines for parallel group trials [26]. Additionally, the
report will follow the CONSORT extensions on prag-
matic and non-pharmacologic trials [27, 28].
Description of data
Baseline comparability of randomly assigned groups
Baseline descriptions of participants’ demographic and
clinical data will be reported by treatment group and
overall. Minima and maxima, means and standard devia-
tions, and medians and quartiles will be used for con-
tinuous variables as appropriate. Frequencies and
proportions will be presented for categorical variables.
No significance testing will be used to test baseline dif-
ferences between the trial arms.
Adherence to allocated treatment
Adherence is defined as being in attendance at the be-
ginning and end of each of the two days of the self-
management course. Adherence versus non-adherence
with the treatment will be described in terms of baseline
variables. The reasons for withdrawal from treatment
will be summarised. Treatment adherence will be de-
scribed by using attendance and reasons for non-
attendance.
Loss to follow-up and missing data
Withdrawal from trial follow-up (attrition) will be re-
ported by intervention group. Moreover, the proportions
of participants who are missing values on each variable
will be summarised by trial arm and time point.
The baseline characteristics of those missing follow-up
will be compared with those with complete follow-up.
The relationship between baseline characteristics and
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missing data will also be investigated graphically. Factors
affecting missingness will be examined by using logistic
regression for a missingness variable. This will be done
by generating a binary variable for missingness at 12
months after randomisation and regressing this on pre-
randomisation (baseline) variables. All outcome variables
will be assessed before choosing a representative
selection.
The relationship between compliance and loss to
follow-up will be assessed. This will be done by using
binary variables for completion of all training sessions
and for drop-out at 12 months. The relationship be-
tween these variables will be tested by using a chi-
squared test. The results of these analyses will inform
the need to use multiple imputation (MI) in the formal
analysis. This is because these post-randomisation vari-
ables cannot be included as covariates in the model
without changing the meaning of the results.
Adverse events
AEs, adverse reactions, serious AEs, and serious adverse
reactions will be summarised by treatment arm.
Descriptive statistics for outcome measures
Each of the outcome measures will be described by
treatment group and time point. Means and standard
deviations or medians and interquartile ranges will be
used for continuous variables; box plots, histograms, and
Q-Q plots will be used to assess whether the distribution
of a variable is normal. Frequencies and proportions will
be used to describe categorical variables.
Inference and modelling
Inferential analysis
The main statistical analyses will estimate the difference
in mean outcomes between patients randomly assigned
to SMILE and TAU versus TAU alone by ITT (i.e., treat-
ment groups defined by result of randomisation rather
than treatment received) at the various post-treatment
observation time points. This will be done by using
mixed-effects linear regression modelling for longitu-
dinal data, including outcome measures at all time
points and conditioning on the stratification variable
(treatment centre) and baseline measures. Group differ-
ence estimates and associated confidence intervals will
be reported.
Missing post-randomisation assessments will be dealt
with by fitting adequate linear mixed models to all the
variables by using maximum likelihood (ML) methods.
Such an approach provides valid inferences under the
assumption that the missing data mechanism is ignor-
able (missing at random, or MAR) and provided that
predictors of missingness are included as covariates in
the model.
Group difference estimates and associated 95 % confi-
dence intervals will be reported. The trial statistician will
remain blind until the main analyses have been com-
pleted. Some analyses, such as modelling training group
effects, estimating complier average causal effects
(CACEs), and summarising numbers trained by each
educational facilitator, cannot be performed blind. Such
analyses will be carried out last in order to preserve
blindness for as long as possible.
The significance level will be 5 % (two-sided) for the
primary outcome. Secondary analyses will be carried out
at the 5 % level but will have to be interpreted with care
as multiple testing is not taken account of. Sensitivity
analyses will be used to assess the robustness of conclu-
sions to non-ignorable missing outcome data.
Analysis of primary outcome
The analysis population will include all randomly
assigned patients. The primary outcome is quality of life,
as measured by the QOLIE-31, at 12 months after ran-
domisation. Quality of life at both post-treatment time
points (6 and 12 months after randomisation) will be
modelled simultaneously. These outcomes will constitute
the dependent variable, and quality of life at baseline,
treatment centre, baseline predictors of drop-out, trial
arm, time dummy variables, and a treatment*time inter-
action term will be included as explanatory variables.
This last term will allow the model to provide the treat-
ment effect estimate at the primary time point (12
months after randomisation). The covariance matrix of
the repeated measures will be carefully modelled: an un-
structured covariance matrix and the covariance matrix
implied by a participant-varying random intercept model
will be formally compared, and the best covariance
structure will be identified. This analysis is valid pro-
vided that missing values in quality-of-life outcomes are
MAR. This is to say that, given the observed variables
that have been included in the analysis model, the miss-
ingness pattern does not depend on any unobserved/
unmodelled data.
The relationship between baseline variables and miss-
ing outcome data will be assessed by using logistic
regression with an outcome variable that represents
whether outcome quality-of-life data are present or
missing. Should any baseline variables be predictive of
missingness, these will be included in the model as co-
variates. Should the post-treatment variable “compliance
with treatment” predict missingness, MI will be used to
approximate an ML estimator under this form of MAR
[29]. The impact of departures from MAR on treatment
effects will be assessed by using sensitivity analysis [30].
Potential clustering due to participants attending the
same educational group (and therefore sharing the same
interventionist) in the SMILE arm will also be assessed
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by exploring the variability between these groups. This
will be summarised by using the ICC. It is expected that
a statistical dependence will exist and that this will need
to be addressed in the modelling process. Therefore, it is
anticipated that models will need to include random ef-
fects that vary with educational group in this trial arm.
Analysis of secondary outcomes
Secondary patient outcomes relating to the quality of life
(at 6 months after randomisation), impact of epilepsy,
medication management, psychological distress, and
mastery/control of epilepsy will be analysed by using lin-
ear mixed models and an approach similar to that de-
scribed above.
Medication adverse effects and perceived stigma are
unlikely to be normally distributed. Transformations will
be investigated for these outcomes. Failing this, other
types of mixed models, such as a mixed logistic model,
will be considered.
Seizure frequency as measured by using the scale of
Thapar et al. is a count variable and will be analysed by
using a type of Poisson mixed model, and allowance will
be made for overdispersion/varying exposure periods.
Seizure frequency using the scale of Baker et al. is an or-
dinal variable and will be analysed by using a mixed or-
dinal logit model.
Time (days) elapsed since last seizure is measured pre-
randomisation (at baseline) and at 6 and 12 months after
randomisation. Such a variable will be analysed after a
log transformation. If the data are truncated, survival
modelling will be considered.
Statistical considerations
Stratification and clustering
Randomisation is stratified by treatment centre (of
which there are up to 15). Therefore, it is important to
include this variable as a covariate in the modelling
process. The structure of the majority of the data is lon-
gitudinal, and repeated measurements are taken at base-
line and 6 and 12 months after randomisation. This
correlation between participants’ repeated observations
is being taken into account by a modelling process for
the covariance matrix. It is also possible that clustering
will be seen within educational facilitators/educational
groups within the SMILE arm.
Missing scale items
The number (percentage) with complete data will be re-
ported. The ideal approach is to use missing value guid-
ance provided by the developers of the scales. When
such guidance is not available, scales will be prorated for
an individual if not more than 20 % of items are missing.
For example, in a scale with 10 items, prorating will be
applied to individuals with one or two items missing.
The average value for the eight or nine complete items
will be calculated for that individual and used to replace
the missing values. The scale score will be calculated on
the basis of the complete values and these replacements.
Missing baseline data
Missing baseline data should not be a problem. How-
ever, if we encounter missing baseline values of outcome
variables, these can be singly imputed according to
White and Thompson [31] without incurring bias in trial
arm effect estimates.
Missing outcome data
Where there are two outcome time points, missing post-
randomisation assessments will be dealt with by fitting
linear mixed models to all the available data by using
maximum likelihood methods. Such an approach pro-
vides valid inferences under the assumptions that the
missing data mechanism is ignorable (or MAR) and that
pre-randomisation data are available for the scale. If
post-treatment variables such as compliance with treat-
ment are found to be predictive of drop-out, multiple
imputation will be considered. This will be assessed
through the use of a chi-squared test of independence.
Method for handling multiple comparisons
For the primary outcome, no formal adjustment of the P
value for multiple testing is necessary. The analyses of
the secondary outcomes will also not be adjusted for
multiple outcome comparisons. Thus, care should be
taken in the interpretation of inferences for the numer-
ous secondary outcomes. (Results will need to be inter-
preted as hypotheses-generating and subject to
replication.)
Method for handling non-compliance
In addition to the primary ITT analysis, the effect of ac-
tually receiving treatment as defined in the protocol (its
efficacy) will be estimated for the primary outcome. If
non-adherence with the active treatment is high, a
CACE-type analysis will be considered. Specifically, in-
strumental variable (IV) methods will be used to assess
the efficacy of the SMILE treatment. Such methods
evaluate the causal effect of SMILE on a clinical out-
come in the subpopulation who would comply with
SMILE. The application of IV methods for explanatory
evaluation of randomised controlled trials has been ad-
vocated because random allocation itself provides a
strong instrument for treatment receipt [32]. IV regres-
sion will be carried out by using the two-stage least
squares estimator as implemented in the Stata command
“ivregress 2sls”.
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Model assumption checks
The models assume normally distributed outcomes; this
will have been checked when describing the data, and if
substantial departures from normality occur, transforma-
tions will be considered. Residuals will be plotted to
check for normality and inspected for outliers. This is
expected to be unnecessary for the primary outcome but
will be undertaken partly in order to explore the data
and to maintain a consistent method for all outcomes.
Sensitivity analyses
The impact of departures from MAR on treatment ef-
fects of continuous outcomes will be assessed by using
sensitivity analysis. This will be done for the quality-of-
life outcomes and will be based on the investigators’
opinion about the range of possible mean differences in
outcome between those with missing data and those
with observed values in the two trial arms [30].
Planned subgroup analyses
The trial has not been designed (powered) to assess
treatment effects within subgroups. As a consequence,
no such subgroup analyses are described.
Software
Data management will employ an online data collection
system for clinical trials (MACRO; InferMed Limited,
London, UK). This is hosted on a dedicated server at
King’s College London and managed by the KCTU. The
KCTU Data Manager will extract data periodically as
needed. Stata will be used for data description and the
main inferential analysis.
Economic analysis plan
Heath economic objectives (secondary objective 11)
We will take both a health service and a societal per-
spective in the economic evaluation. The costs of the
intervention will be calculated by taking into account
staff time needed for training, supervision, and delivery
of the educational session and will also include over-
heads and capital costs. The cost per session will be esti-
mated by combining the above information with activity
data. The Client Service Receipt Inventory will be
adapted and used to record the use of other services and
also unpaid carer time and time lost from work. The ser-
vice use data will be combined with relevant unit cost
information [33]. Lost employment costs will be calcu-
lated by combining lost work time with average wage
rates. Health-care and societal costs at follow-up will be
compared between the two arms by using a regression
model with baseline costs controlled for. Cost data are
often skewed, and we will use bootstrapping to generate
95 % confidence intervals around the cost differences.
To assess cost-effectiveness, we will combine costs with
data for the primary outcome measure at 12 months.
Cost utility will be assessed by combining costs with
quality-adjusted life years (QALYs), which will be gener-
ated from the European Quality of Life-5 Dimensions
(EQ-5D) questionnaire. If the intervention results in bet-
ter outcomes and lower costs, it will be considered to be
“dominant”. If it results in better outcomes and higher
costs, incremental cost-effectiveness ratios will be calcu-
lated to show the extra cost incurred to achieve a one-
unit improvement on the QOLIE-31 or one extra QALY
(both at 12 months). Uncertainty around the estimates
of cost-effectiveness and cost utility will be made by tak-
ing 1000 cost-outcome combinations at random (and
with replacement) from the data by using bootstrap
methods and plotted on a cost-effectiveness plane. Inter-
pretation of the results will use cost-effectiveness accept-
ability curves to show the probability that the
intervention is the most cost-effective option for a range
of different values placed on an improvement in out-
come. For QALYs, the range will be £0 to £100,000. The
range for improvements on the QOLIE-31 will be
chosen so that values at which the intervention or TAU
has a 50 % and 70 % and 90 % likelihood of being cost-
effective are identified.
Economic measures
Client Services Receipt Inventory: This will record con-
tacts with health-care services at baseline and over the
follow-up. It includes hospital admissions, contact with
primary and community care, and receipt of care from
family and friends. In addition, it includes lost work
time.
EQ-5D: QALYs will be calculated from the EQ-5D
health state classification instrument. This covers five
domains: mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression. For each domain, the
respondent chooses one of five levels of functioning,
from good to poor. The five levels for each of the five
domains are used to define unique health states to which
a pre-estimated “utility” value will be attached.
Qualitative analysis plan (secondary objective 12)
Aim
Qualitative studies are increasingly conducted as a com-
ponent of the evaluation of “complex” interventions with
the aim of supplementing quantitative measures and
contributing to the wider implementation of health-care
interventions [34]. The present study aimed to comple-
ment the quantitative measures by providing an in-
depth account of (1) participants’ perceptions of what
they valued and any negative aspects of the intervention
and (2) whether and in what ways participants continued
to make use of the training received.
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Methods
Study group
Pilot interviews at 12 months post-intervention have in-
dicated that participants were often not able to recall
whether they had learned particular information about
epilepsy and its management from the intervention or
through other sources. This supports evidence that on-
going seizures do impair the laying down of memory
[35]. However, reducing the period between intervention
and interviews would have possible implications for sub-
sequent outcome measurement. Therefore, we will inter-
view the control group participants 2–6 months after
they have received the control group intervention and
have completed the three phases of quantitative data
collection.
Recruitment
The study will be based on around 20–24 study partici-
pants who were randomly assigned to the SMILE (UK)
control group, and the precise sample number will de-
pend on when sampling saturation has been achieved
and the condition that no new issues or explanations are
elicited by further interviews [36]. Participants will be
selected purposively to achieve a study group that is in-
clusive in terms of differences in gender, age, ethnicity,
severity of seizures, and depression score.
Interviews
These will take place at participants’ homes or a con-
venient public place if preferred. Interviews will be semi-
structured and conducted in a conversational manner
with probes, facilitation, and clarification of responses as
required. The topics covered will include participants’
experiences in taking part in the courses, their percep-
tions of things they valued and found of particular bene-
fit and any negative aspects as well as any factors that
encouraged or hindered their participation in the
courses and whether and in what ways they have contin-
ued to make use of the training. The content of the
course workbook will also be discussed in relation to
participants’ own needs and lifestyles.
Analysis
The interviews will be audio-recorded (with consent)
and transcribed. The analysis will proceed alongside data
collection and will be based on a framework approach
[37]. This is suitable for small numbers of cases and en-
sures that each case is fully taken into account in the
analysis. This analytic approach requires identifying ini-
tial themes that are then grouped into main and sub-
themes. This is applied to the raw transcript data for
each interview, and a thematic “chart” is created that
summarises information for each theme and allows
cross-case and within-case analysis through a process of
constant comparison, and particular attention is paid to
deviant cases. This approach to analysis can be under-
taken manually or by using new framework matrices
from NVivo9 or 10. Two members of the research team
will participate in data analysis to reduce bias in the
identification and interpretation of themes and
categories.
Outputs
The findings of this nested qualitative study will contrib-
ute to outcome assessment of the trial by providing expla-
nations and a greater understanding of the quantitative
assessment as well as exploring issues not covered by
these assessments. The findings may also be written up as
a stand-alone article that examines patient-based assess-
ments of a self-management intervention.
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